The role of α-synuclein and tau in neurodegenerative movement disorders

Current Opinion in Neurology

Volumn 18, Issue 4, 2005, Pages 357-362

  Wenning, Gregor K ^a   Jellinger, Kurt A ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; GAMMA SYNUCLEIN; TAU PROTEIN;

COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; EDITORIAL; EXTRAPYRAMIDAL SYNDROME; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; SHY DRAGER SYNDROME; TANDEM REPEAT;

EID: 23344452885     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000168241.53853.32     Document Type: Editorial

References (56)

1. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10:1055-1063.
2. Jellinger KA. General aspects of neurodegeneration. J Neural Transm Suppl 2003; 65:101-144.
3. Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM. Protein misfolding in neurodegenerative diseases. Neuropathol Appl Neurobiol 2004; 30:215-224.
4. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004; 10(Suppl.):S10-S17.
5. Citron BA, Suo Z, SantaCruz K, et al. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 2002; 40:69-78.
6. Trojanowski JQ. Protein aggregation. In: Dickson DW, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Los Angeles, USA: ISN Press; 2003. pp. 11-13.
7. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295:1852-1858.
8. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24(11 Suppl.):S7-S14.
9. McNaught KS, Shashidharan P, Perl DP, et al. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002; 16:2136-2148.
10. McNaught KS, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179:38-46.
11. Dickson DW, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropathology Press; 2003.
12. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301I tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293:1491-1495.
13. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98:12245-12250.
14. Spillantini MG, Murrell JR, Goedert M, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998; 95:7737-7741.
15. Kang JH, Kim KS. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Mol Cell 2003; 15:87-93.
16. Paik SR, Lee D, Cho HJ, et al. Oxidized glutathione stimulated the amyloid formation of alpha-synuclein. FEBS Lett 2003; 537:63-67.
17. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003; 179:9-16.
18. Martinez J, Moeller I, Erdjument-Bromage H, et al. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J Biol Chem 2003; 278:17379-17387.
19. Sharon R, Bar-Joseph I, Frosch MP et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003; 37:583-595.
20. Sharon R, Bar-Joseph I, Mirick GE, et al. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem 2003; 278:49874-49881.
21. Antony T, Hoyer W, Cherny D, et al. Cellular polyamines promote the aggregation of alpha-synuclein. J Biol Chem 2003; 278:3235-3240.
22. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18(Suppl. 6):S2-S12.
23. Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol (Berl) 2005; 109:129-140.
24. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann NY Acad Sci 2003; 991:93-100.
25. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3:1301-1306.
26. Bonini NM, Fortini ME. Human neurodegenerative disease modeling using Drosophila. Annu Rev Neurosci 2003; 26:627-656.
27. Goedert M. Introduction to the tauopathies. In: Dickson DW, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Press; 2003. pp. 82-85.
28. Tolnay M, Probst A. Review: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 1999; 25:171-187.
29. Jellinger KA. Neuropathology and tau. In: Hanin I, Cacabelos R, Fisher A, editors. Progress in Alzheimer's and Parkinson's disease. Lancaster, UK: Parthenon Publishing; 2005. in press.
30. Zhukareva V, Shah K, Uryu K, et al. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease: a comparative study. Am J Pathol 2002; 161:1135-1141.
31. Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61:935-946.
32. Trojanowski JQ, Dickson D. Update on the neuropathological diagnosis of frontotemporal dementias. J Neuropathol Exp Neurol 2001; 60:1123-1126.
33. Munoz DG, Dickson DW, Bergeron C, et al. The neuropathology and biochemistry of frontotemporal dementia. Ann Neurol 2003; 54(Suppl. 5): S24-S28.
34. Jellinger KA. Experimental models of synucleinopathies. In: Dickson DW, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel, Switzerland: ISN Neuropathology Press; 2003pp. 215-223.
35. Lauwers E, Debyser Z, Van Dorpe J, et al. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 2003; 13:364-372.
36. Maries E, Dass B, Collier TJ, et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003; 4:727-738.
37. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300:636-640.
38. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293:1487-1491.
39. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43:321-332.
40. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl) 2002; 104:7-11.
41. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
42. Kotzbauer PT, Giasson BI, Kravitz AV, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 2005; in press.
43. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62:1619-1622.
44. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44:601-607.
45. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44:575-577.
46. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004; 111:219-235.
47. Parkkinen L, Kauppinen T, Pirttila T, et al. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005; 57:82-91.
48. McKeith IG, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3:19-28.
49. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003; 62:644-654.
50. Iseki E, Takayama N, Furukawa Y, et al. Immunohistochemical study of synphilin-1 in brains of patients with dementia with Lewy bodies - synphilin-1 is non-specifically implicated in the formation of different neuronal cytoskeletal inclusions. Neurosci Lett 2002; 326:211-215.
51. Mamah CE, Lesnick TG, Lincoln SJ, et al. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann Neurol 2005; 57:439-443.
52. Chiba-Falek O, Touchman JW, Nussbaum RL. Functional analysis of intraallelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum Genet 2003; 113:426-431.
53. Arai K, Kato N, Kashiwado K, Hattori T. Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett 2000; 296:171-173.
54. Arima K, Mizutani T, Alim MA, et al. NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathol (Berl) 2000; 100:115-121.
55. Iseki E, Marui W, Kosaka K, Ueda K. Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 1999; 265:9-12.
56. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 2004; 27:129-134.